FDA gave final approval to required safety labeling updates for opioids. The updates, first included in an April 2023 drug safety communication, include the addition of language stating the risk of overdose increases with higher doses for all opioid analgesics and that immediate-release opioids should not be used for an extended period of time unless a patient’s pain is so severe that it cannot be controlled otherwise.

CDC alerted health care professionals concerning the important need to get Americans vaccinated against influenza, COVID-19, and respiratory syncytial virus (RSV) during the 2023–2024 cold season.

Many states have now legalized cannabis, and pregnant parents often turn to the substance to relieve nausea and pain. However, new data reveal a link to negative pregnancy outcomes.

A new study published in JAMA concludes that long-term use of the GLP-1 receptor agonist tirzepatide may be necessary to prevent weight gain.

FDA inspections of drug manufacturing facilities in the United States and overseas declined well below pre-pandemic levels between 2020 and 2022, according to a new study in Health Affairs.